Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

A clinical-stage biopharmaceutical company was looking to collaborate on a randomized Phase II study conducted at multiple centers. The study aimed to evaluate the efficacy of a modified synthetic peptide in patients diagnosed with exocrine pancreatic cancer. To accomplish these goals, the sponsor needed help with biostatistics and programming, data management, monitoring and site management, medical safety, quality assurance, and medical writing.

Learn how they were able to reach a unanimous decision after a safety review committee data review meeting to close Phase II and advance to Phase III.